Please ensure Javascript is enabled for purposes of website accessibility

3 Stocks More Than 25% Off Their 2021 Highs That Could Still Make You Rich

By Keith Speights - Mar 29, 2021 at 5:52AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

All three of these stocks appear to be great comeback candidates.

You've no doubt heard the investing adage to "buy the dip." But what if the dip is a really bad one? Sometimes buying stocks that fall significantly isn't such a great idea.

On the other hand, there are other cases where scooping up shares when they've retreated a lot can pay off in a big way over the long run. Here are three stocks more than 25% off their 2021 highs that could still make you rich.

Three dollar signs that are arranged higher from left to right

Image source: Getty Images.

1. Editas Medicine

Editas Medicine (EDIT -1.09%) delivered a sizzling gain of 137% last year. However, that sizzle has definitely fizzled in recent months. The biotech stock has plunged 55% from its high set in early January.

You can blame musical chairs in Editas' executive ranks for much of its decline. In January, Chief Scientific Officer Charles Albright left the company. Less than a month later, board Chairman Jim Mullen replaced Cynthia Collins as CEO.

Don't count Editas out, though. The company expects to report results from its early-stage clinical study evaluating EDIT-101 in treating rare genetic eye disease Leber congenital amaurosis 10 later this year. It recently kicked off a phase 1/2 study of EDIT-301 in treating sickle cell disease. Editas plans to file for U.S. Food and Drug Administration (FDA) approval by the end of 2021 to advance EDIT-301 into clinical testing targeting another rare genetic blood disorder, beta-thalassemia.

If either of its lead candidates proves to be successful in clinical studies, Editas could easily regain and overtake its previous highs. Over the long run, the company's CRISPR gene editing technology could be used to treat many other genetic diseases as well as cancer. Editas is a risky stock, but one that could still be a massive winner.

2. Brookfield Renewable

I really expected that Brookfield Renewable (BEPC 1.05%) would take off in 2021. The Biden administration has made clean energy a top priority. Brookfield Renewable is a leader in renewable energy. However, the stock has fallen 27% from its high earlier this year.

What happened? The company's parent, Brookfield Asset Management, sold 15 million shares of Brookfield Renewable in a secondary public offering. This action sparked the renewable-energy stock's decline.

Brookfield Renewable's prospects remain as bright as ever, though. The company expects that a whopping $100 trillion will be spent on reducing carbon emissions over the next three decades. That should translate to strong growth for renewable power.

The company's current capacity stands at 19 gigawatts. Brookfield Renewable's development pipeline could add another 23 gigawatts of capacity. I still think this stock will take off in a major way in the not-too-distant future.

3. Trupanion

Trupanion's (TRUP -4.26%) shares more than tripled last year. The story for the pet medical insurance provider hasn't been so great in 2020 so far, though, with its shares tumbling 39% from the peak in February. 

The primary culprit behind Trupanion's dismal performance was its Q4 update. The company posted a net loss of $0.09 per share, which was much worse than the consensus analysts estimate of a net loss of $0.03 per share. 

However, Trupanion should deliver strong growth. It expects total revenue in 2021 to jump 32% year over year, with subscription revenue increasing by 25%. The company's bottom line might not improve as much, but it's because Trupanion plans to increase investments in new products and international expansion. This higher spending should pay off over the long term.

Trupanion's partnership with Aflac should also begin to reap returns beginning in 2022. The big supplement insurance company plans to offer Trupanion's pet insurance to its large and medium-sized businesses first. In 2023, the two companies hope to expand their focus to the small-business market.

The opportunities for growth in pet medical insurance are huge, with a market penetration rate in the U.S. of around 1%. I don't think Trupanion's slump will last for too much longer. The current pullback looks like a great time to buy this stock and hold it to obtain tremendous returns over the next few years.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Trupanion Stock Quote
$61.76 (-4.26%) $-2.75
Brookfield Asset Management Inc. Stock Quote
Brookfield Asset Management Inc.
$46.93 (-0.34%) $0.16
Aflac Incorporated Stock Quote
Aflac Incorporated
$56.58 (2.71%) $1.49
Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
$10.90 (-1.09%) $0.12
Brookfield Renewable Corporation Inc. Stock Quote
Brookfield Renewable Corporation Inc.
$36.98 (1.05%) $0.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.